Preclinical results presented at the European Academy of Dermatology
[by Yu, Suin] Shaperon announced in September that it has presented preclinical study results for its alopecia areata treatment candidate, SH1010337, at the European Academy of Dermatology and Venereology (EADV). Discovered through the company’s AI-driven drug development platform, AIDEN, the candidate demonstrated effectiveness in promoting hair growth by modulating the immune system. Notably, this research is regarded as a potential game-changer, as SH1010337 represented the first alopecia areata therapy to target GPCR 19.
SH1010337 is an innovative compound developed through AI-driven analysis of 카지노 바카라's decade-long accumulation of inflammasome data. The company’s proprietary platform, AIDEN, harnesses this extensive dataset to scientifically design and discover even complex targets like GPCR 19.
Hair loss is typically classified into hormonally driven ‘male pattern baldness’ and autoimmune-related ‘카지노 바카라 areata.’ The latter not only causes a significant decline in quality of life but can also progress rapidly from localized patches to total scalp hair loss, and in severe cases, complete body hair loss. According to the company, 카지노 바카라 areata remains a difficult condition to treat due to its high recurrence rate. Current therapies, such as JAK inhibitors, face notable limitations, including side effects, concerns over long-term safety, treatment costs, and relapse following discontinuation, underscoring a substantial unmet medical need, particularly among severe cases and pediatric patients.
Amid intensifying competition in the hair loss treatment field, Shaperon has pioneered the world's first immune-regulation-based approach for 카지노 바카라 areata, building on extensive research into GPCR 19. SH1010337 works by suppressing the overactivation of inflammatory complexes while enhancing regulatory T cells (Tregs), effectively restoring balance to the scalp’s immune system. In preclinical models of autoimmune disease. In preclinical models of autoimmune-driven 카지노 바카라 areata, the therapy demonstrated efficacy in promoting hair follicle regeneration.
In a representative preclinical model of 카지노 바카라 areata, the ‘lymph node-derived cell (LNC)-induced mouse model,’ SH1010337 achieved a marked reduction in bald patches. Whereas competing JAK inhibitors delivered a recovery rate of around 62%, SH1010337 demonstrated superior efficacy with a 74% recovery rate. The company noted that the candidate not only showed stronger immune modulation and hair regeneration than existing treatments but also holds promise in mitigating the broad immunosuppression and relapse risk commonly associated with current treatment options.
Notably, the discovery of the candidate was powered by 카지노 바카라’s advanced AI platform, AIDEN. The company further commented that his approach not only accelerated the development timeline compared to conventional drug discovery methods but also enabled integrated activity and toxicity predictions, along with optimized chemical property design, through proprietary algorithms and large-scale dataset learning.
The company highlighted that one of the key differentiators lies in learning from the repeated failures of global pharmaceutical firms that have faced in developing GPCR 19-targeted therapies, which informed a more refined design approach. Leveraging years of accumulated big data, AIDEN has delivered meaningful results in novel drug design, as well as in toxicity and activity prediction, areas long considered difficult to overcome with conventional algorithms.
"Our proprietary AI-driven GPCR 19-targeted therapy demonstrates clear advantages over JAK inhibitors, particularly in restoring immune balance and ensuring long-term safety. This preclinical study is especially meaningful as it highlights the potential to expand applications beyond 카지노 바카라 areata to a broad spectrum of autoimmune diseases," a Shaperon official remarked. "NuGel, the parent compound of SH1010337, is an atopic dermatitis treatment candidate that has already shown strong anti-inflammatory effects and favorable safety in Phase 2 clinical trials conducted in the U.S. and Korea. Based on this foundation, SH1010337 is expected to demonstrate high safety in humans."
Conversely, the global market for 카지노 바카라 areata treatments is forecasted to expand from around USD 3.8 billion (approximately KRW 5 trillion) in 2025 to about USD 6.9 billion by 2034.